EP1085883A1 - Composition pharmaceutique a base de sels d'acide gras d'erythromycine pour le traitement topique de maladies de la peau - Google Patents

Composition pharmaceutique a base de sels d'acide gras d'erythromycine pour le traitement topique de maladies de la peau

Info

Publication number
EP1085883A1
EP1085883A1 EP00920654A EP00920654A EP1085883A1 EP 1085883 A1 EP1085883 A1 EP 1085883A1 EP 00920654 A EP00920654 A EP 00920654A EP 00920654 A EP00920654 A EP 00920654A EP 1085883 A1 EP1085883 A1 EP 1085883A1
Authority
EP
European Patent Office
Prior art keywords
erythromycin
fatty acid
pharmaceutical composition
skin
acne
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00920654A
Other languages
German (de)
English (en)
Inventor
Ulrich Knie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr August Wolff GmbH and Co KG Arzneimittel
Original Assignee
Dr August Wolff GmbH and Co KG Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr August Wolff GmbH and Co KG Arzneimittel filed Critical Dr August Wolff GmbH and Co KG Arzneimittel
Publication of EP1085883A1 publication Critical patent/EP1085883A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Definitions

  • the present invention relates to a pharmaceutical composition based on erythromycin fatty acid salts with 12 to 22 carbon atoms in the fatty acid residue and the use of these erythromycin fatty acid salts for the topical treatment of skin diseases.
  • Acne is a skin disease that is particularly common in adolescents. Acne is characterized by a purulent rash, which mainly occurs on the face, neck and chest. It is caused by the infection of enlarged sebaceous glands of the skin with Propionibacterium acnes, which are present on the surface of the skin. This leads to the formation of pus-filled vesicles in the area of the sebaceous glands of the skin (Herder, Lexicon of Biology, Spektrum Akademischer Verlag, Heidelberg, 1994, p. 87). An essential aspect for the development and maintenance of acne is the formation of free fatty acids in the sebaceous gland follicle, which are caused by the lipase of Propionibacterium acnes. The causes of acne are numerous.
  • Erythromycin is broadly effective against one with low toxicity Numerous Gram-positive bacteria, e.g. Streptococcus and Staphylococcus as well as some Gram-negative bacteria, e.g. Neisse a and Haemophilus, as well as against mycoplasmas (Römpp Chemie-Lexikon, Georg Thieme Verlag, Stuttgart, 1997, p. 1210).
  • erythromycin The main indication of erythromycin is acne-papulo-pustulosa (Niedner, Ziegenmayer, Dermatika,ticianliche Veriagsgesellschaft, 1992, p. 94). Under the influence of erythromycin, the free fatty acids formed are reduced. On the one hand, bacteria are reduced due to the antibacterial effectiveness of erythromycin, on the other hand, a direct effect on the lipase can also be demonstrated, whereby erythromycin concentrations are necessary which are below the minimum inhibitory concentration (MIC). In addition, there is a decrease in leukocyte chemotaxis, which leads to a decrease in inflammation.
  • MIC minimum inhibitory concentration
  • Treatment with antibiotics and erythromycin in particular can be divided into oral administration and external administration.
  • Both erythromycin and erythromycin stearate are on the market for oral use in approved drugs for the treatment of acne and skin infections.
  • oral administration gives good effectiveness in combating acne, systematic administration has the disadvantage that the entire organism is strained. Furthermore, the active ingredient is inevitably diluted in the body in this application.
  • GB-A-1 152 644 proposes a stable composition of erythromycin in an oil, the oil having 6 to 18 carbon atoms and an iodine number below 42.
  • erythromycin is relatively stable, however, the use of fatty carriers in the therapeutic treatment of acne is not particularly desirable because the compositions do not allow adequate release of the antibiotic. Furthermore, the composition does not immediately penetrate the skin. Since the skin of acne patients is naturally oily, oil-containing constituents are not adequate carriers. Rather, the skin of the acne patient requires low-fat preparations.
  • a preferred vehicle for the active ingredients in acne therapy are O / W (oil-in-water) creams or emulsions which contain only a low fat content but a high water content. Due to the skin-adequate properties of these formulations, the antibiotics can be easily absorbed by the skin and are therefore particularly effective in acne therapy. However, it has been found in studies that the effectiveness of erythromycin in emulsions with a high water content decreased by up to 60% of the initial value when stored for one month at 25 ° C. (International Journal of Pharmaceutics, 67 (1991) 195-199) . Due to this instability of the aqueous preparations based on erythromycin and the resulting reduced shelf life of the product, industrial production and marketing of o / w creams or emulsions based on erythromycin is not possible.
  • W / ⁇ (water-in-oil) emulsions retained an activity of more than 90% of the initial value after storage for 12 weeks.
  • Alcoholic solutions and alcoholic gels had a slightly reduced shelf life, with storage at 25 ° C for the alcoholic solution, a loss of 10% during the first three weeks and for the alcoholic gel, a loss of 20% after two months .
  • erythromycin is particularly active in the alkaline range, but adjusting the pH to 8.5 had a deleterious effect on the activity of the active ingredient.
  • drugs based on erythromycin for topical use are offered almost exclusively in alcoholic vehicles.
  • US-A-4 000 263 describes a solution based on erythromycin with good storage stability, the erythromycin being dissolved in a carrier consisting of propylene glycol, ethyl alcohol and polyoxyethylene-lauric alcohol.
  • a storage-stable composition is proposed in US Pat. No. 4,469,684 in which the erythromycin is present in the form of its zinc salt in t-butanol.
  • DE-A-37 12 758 describes a stable anti-acne composition based on erythromycin, in which the erythromycin is present in a pharmaceutically acceptable carrier which contains 20 to 99.5% by weight of methyl ether of propylene glycol or of di- contains propylene glycol.
  • compositions are described in FR-A-7707785, FR-A-7732761 and in EP-A-8020929, in which the erythromycin is also present in a carrier made of a polyol, a fatty alcohol or a fatty acid ester.
  • the object of the present invention to provide a pharmaceutical composition for the treatment of skin diseases, in particular acne, the composition remaining stable even when stored over a longer period of time, high effectiveness, good penetration into the skin and a high level Has skin tolerance.
  • the composition should preferably be applied topically.
  • This object is achieved according to the invention by a pharmaceutical composition which contains at least one erythromycin fatty acid salt with 12 to 22 carbon atoms in the fatty acid residue and a liquid or viscous carrier.
  • the present invention further relates to the use of erythromycin fatty acid salts with 12 to 22 carbon atoms in the fatty acid residue for the topical treatment of skin diseases.
  • the erythromycin-C 2-22 fatty acid salt used according to the invention can be used as a free base for topical treatment instead of conventionally used erythromycin.
  • the erythromycin derivative in the form of a C 2-22 fatty acid salt which is used according to the invention, can contain saturated or unsaturated, as well as branched or unbranched fatty acids and mixtures thereof.
  • Preferred examples of usable fatty acids are myristic acid, palmitic acid, lauric acid and stearic acid.
  • Erythromycin stearate is particularly preferably used as an active ingredient in the pharmaceutical composition according to the invention.
  • the erythromycin C ⁇ 2-22 fatty acid salts can be prepared in a manner known per se by conventional methods.
  • the erythromycin base isolated from culture solutions of Streptomyces erythreus can be dissolved in an organic solvent such as acetone. Then the solution obtained is mixed with the fatty acid or fatty acid mixture.
  • the practically pure erythromycin fatty acid salt fails.
  • the pharmaceutical composition containing erythromycin C ⁇ 2-22 fatty acid salt in a pharmaceutically effective amount preferably used in an amount of 0.5 to 10% by weight, more preferably 1 to 5% by weight, based on the total amount of the pharmaceutical composition.
  • the effectiveness of the erythromycin C ⁇ 2-22 fatty acid salt in one around the fatty acid content increased amount as high as the activity of erythromycin as the free base in the same vehicle. The use of this derivative does not lead to a loss of effectiveness in acne therapy.
  • the pharmaceutical composition also contains a liquid or viscous carrier which can be chosen from conventional pharmaceutical carriers.
  • the carrier is preferably selected so that the composition obtained is suitable for topical application. It is particularly preferred that this carrier is in the form of an emulsion, suspension, cream or gel in order to allow the composition to be applied to the skin without problems. It is particularly preferred that the carrier has a low fat content and a high water content. In particular, low-fat creams or emulsions, such as O / W creams or emulsions, but also dosage forms with an extremely high water content, such as gels, are preferred. The water content is usually at least approx. 40%, but a water content of almost 100% is possible for purely aqueous carriers. In particular, a water content of 60 to almost 100% is particularly advantageous since the preparation is particularly well absorbed by the skin in this way.
  • fats e.g. Oils and waxes, as well as alcohols
  • the lipid component can be selected from cetearyl octanoate, decyl oleate, medium-chain triglycerides, glyceryl monostearate, stearic acid, cetyl alcohol, liquid wax esters, isopropyl myristate and cetyl palmitate. Cetearyl octanoate, glyceryl monostearate, cetyl alcohol and medium-chain triglycerides are particularly preferably used.
  • the pharmaceutical composition can have a creamy or pasty character, on the one hand, or a liquid, gel-like consistency. It preferably enables rapid penetration into the skin and sebaceous glands.
  • the preparation can contain further pharmaceutically acceptable additives, such as preservatives, fragrances, antioxidants, buffer substances, dyes and / or pigments.
  • preservatives such as preservatives, fragrances, antioxidants, buffer substances, dyes and / or pigments.
  • both the carrier and the other additives are not particularly limited as long as they do not impair the action of the erythromycin C 2-22 fatty acid salt.
  • the pharmaceutical composition can in addition to the Erythromycin-C ⁇ 2 . 22 - Fatty acid salt contains other active substances that are suitable for the treatment of skin diseases. Examples of these active substances are not particularly limited as long as they have the effect of the erythromycin-C ⁇ 2 . 22 Do not interfere with the fatty acid salt.
  • composition according to the invention can contain, for example, adapalene, isotretinoin, tretinoin, metronidazole, benzoyl peroxide, triclosan, hexachlorophene, estradiol, clotrimazole, ketoconazole, miconazole, croconazole, azelaic acid, spironolactone, cyproteradine acetate and mixtures, chloromotone acetate, mixtures, chloromethane.
  • the pharmaceutical composition according to the invention can be produced in a conventional manner.
  • the individual components in particular the liquid carrier and the active ingredient, are combined with one another.
  • these are usually added to the components of the water phase.
  • the fat phase or the water phase can be heated. Both phases are particularly preferably heated before merging.
  • the temperature depends on the respective constituents, but is usually 30 ° C. to 90 ° C., preferably 40 ° C. to 80 ° C. It is also advantageous if the fat phase is slowly added to the water phase with stirring or homogenization.
  • the Erythromycin-C ⁇ 2-22 fatty acid salt can be incorporated after combining the fat and water phase. Prior to the addition of the active ingredient and the resulting mixture is usually cooled to a temperature of 20 to 40 ° C, preferably 25 to 35 C ⁇ .
  • Erythromycin C ⁇ 2-22 fatty acid salts can be used according to the invention for the topical treatment of skin diseases, especially acne.
  • the invention is illustrated by the following examples. However, it is not to be limited to these.
  • Example 2 Cream containing erythromvcin
  • Example 4 Liquid emulsion
  • Example 9 En thromvcin / tretinoin cream
  • a preparation containing the ingredients according to Example 3 was prepared in the following way.
  • the substances of the fat phase ie glycerol monostearate, neutral oil, stearic acid, glyceryl monoricinoleate and glycerin, were weighed together and heated to 75 ° C.
  • the components of the water phase ie water and preservatives, were also heated to 75 ° C. When both phases had reached this temperature, the fat phase was slowly added to the water phase with stirring or homogenization. The emulsion obtained was cooled with stirring.
  • the erythromycin stearate was incorporated at a temperature of approximately 30 ° C. in order to obtain an erythromycin cream. 3. Stability studies
  • a preparation prepared according to Example 1 with 6.12% by weight erythromycin stearate (corresponding to 4.0% by weight erythromycin base) in an O / W cream was stored at 25 ° C. for 6 months. As can be seen from Table 1, there was no significant drop in the content and thus in the effectiveness.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique qui contient au moins un sel d'acide gras d'érythromycine ayant 12 à 22 atomes de carbone dans le reste d'acide gras et un excipient liquide ou visqueux. L'invention concerne également l'utilisation de ces sels d'acide gras d'érythromycine pour le traitement topique de maladies de la peau, en particulier pour le traitement de l'acné. La composition pharmaceutique selon l'invention se caractérise par une grande stabilité, même en cas de stockage prolongé, une bonne pénétration dans la peau et une grande tolérance cutanée.
EP00920654A 1999-04-19 2000-04-03 Composition pharmaceutique a base de sels d'acide gras d'erythromycine pour le traitement topique de maladies de la peau Withdrawn EP1085883A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19917548A DE19917548A1 (de) 1999-04-19 1999-04-19 Pharmazeutische Zusammensetzung auf der Basis von Erythromycin-Fettsäuresalzen mit 12 bis 22 Kohlenstoffatomen im Fettsäurerest und Verwendung dieser Erythromycin-Fettsäuresalze zur topischen Behandlung von Hauterkrankungen
DE19917548 1999-04-19
PCT/EP2000/002950 WO2000062784A1 (fr) 1999-04-19 2000-04-03 Composition pharmaceutique a base de sels d'acide gras d'erythromycine pour le traitement topique de maladies de la peau

Publications (1)

Publication Number Publication Date
EP1085883A1 true EP1085883A1 (fr) 2001-03-28

Family

ID=7905021

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00920654A Withdrawn EP1085883A1 (fr) 1999-04-19 2000-04-03 Composition pharmaceutique a base de sels d'acide gras d'erythromycine pour le traitement topique de maladies de la peau

Country Status (11)

Country Link
EP (1) EP1085883A1 (fr)
AU (1) AU4115100A (fr)
BG (1) BG105093A (fr)
DE (1) DE19917548A1 (fr)
EE (1) EE200000727A (fr)
HR (1) HRP20000884A2 (fr)
HU (1) HUP0102702A3 (fr)
NO (1) NO20006260L (fr)
PL (1) PL344988A1 (fr)
SK (1) SK18652000A3 (fr)
WO (1) WO2000062784A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114632139B (zh) * 2022-04-02 2023-04-07 北京双吉制药有限公司 一种红霉素药膏及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2383667A1 (fr) * 1977-03-16 1978-10-13 Desjonqueres Stephane Medicament contre l'acne
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
IT1210608B (it) * 1980-12-08 1989-09-14 Rorer Int Overseas Composizione per il trattamento topico dell'acne
DE3375376D1 (en) * 1982-10-15 1988-02-25 Procter & Gamble Storage stable topical pharmaceutical composition including nitrogen-containing stabilizers
JPS6021831A (ja) * 1983-07-11 1985-02-04 コ−ニング・グラス・ワ−クス 陰極線管のフエ−スプレ−ト用ガラス
LU86945A1 (fr) * 1987-07-17 1989-03-08 Oreal Compositions pharmaceutiques et cosmetiques a base de pyridones et d'agents antibacteriens
DE19706979A1 (de) * 1997-02-21 1998-08-27 Lindopharm Gmbh Kombinationspräparat für oral applizierbare Erythromycine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0062784A1 *

Also Published As

Publication number Publication date
WO2000062784A1 (fr) 2000-10-26
HRP20000884A2 (en) 2001-10-31
EE200000727A (et) 2002-04-15
NO20006260L (no) 2001-02-19
HUP0102702A2 (hu) 2001-12-28
HUP0102702A3 (en) 2003-02-28
BG105093A (bg) 2001-07-31
AU4115100A (en) 2000-11-02
NO20006260D0 (no) 2000-12-08
DE19917548A1 (de) 2000-10-26
PL344988A1 (en) 2001-11-19
SK18652000A3 (sk) 2001-08-06

Similar Documents

Publication Publication Date Title
EP0582239B1 (fr) Préparation pharmaceutique et/ou cosmétique
DE69029804T2 (de) VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL
DE3686325T2 (de) Hydratierte lipidische lamellare phasen oder liposome mit retinoid oder deren analoga wie karotenoid enthaltende dermatologische, pharmazeutische oder kosmetische zusammensetzung.
DE602005002844T3 (de) Umkehremulsionszusammensetzung mit calcitriol und clobetasol-17-propionat und ihre kosmetische und dermatologische verwendung
DE3341979C2 (fr)
EP1475080B1 (fr) Composition cosmetique pour le traitement du vieillissement de la peau et/ou des peaux stressées
DE69427639T3 (de) Verwendung von nicht-ionischen oberflächenaktiven substanzen in retinoid enthaltenden stabilen topischen zusammensetzungen
DE69500315T2 (de) Kosmetische oder dermatologische Wasser-in-Öl Emulsion mit hohem Gehalt an Hydroxysäuren
EP0367103B1 (fr) Onguent topique
DE4345186C2 (de) Hydrocortison-21-acetat-17-propionat enthaltende W/O-Lotionen
DD298352A5 (de) Tretinoin enthaltende zubereitung und verfahren zu ihrer herstellung
DE4431251C2 (de) Hautcreme
DE60004786T2 (de) Verfahren und zusammensetzung zur behandlung von akne
DE69912760T2 (de) Verwendung von topischen formulierungen des öl-in-wasser typs, enthaltend galaktolipid material als emulsionsmittel, um eine länger anhaltende wirkung eines darin enthaltenen aktiven wirkstoffs zu vermitteln
DE2601489C2 (fr)
DE3411225C2 (fr)
DE3049722C2 (de) Zur Behandlung von Akne und Seborrhoe geeignete, wäßrige Benzoylperoxidzusammensetzung
EP0804150B1 (fr) Lotions contenant des derives d'acide gras
EP0605504B1 (fr) Preparations cosmetiques et dermatologiques
EP0336000B1 (fr) Crème ambiphile
DE19804376B4 (de) Lipidmischungen sowie deren Verwendung
DE2338323C2 (de) Antiseptisches wäßriges Mittel zur Behandlung der Haut
DE60123132T2 (de) Liposomenformulierung mit clobetasol propionate
WO2000062784A1 (fr) Composition pharmaceutique a base de sels d'acide gras d'erythromycine pour le traitement topique de maladies de la peau
EP0455631B1 (fr) Preparation contenant de l'acide salicylique pour traiter des affections dermiques desquamantes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 20001205;LV PAYMENT 20001205;MK PAYMENT 20001205;RO PAYMENT 20001205;SI PAYMENT 20001205

17Q First examination report despatched

Effective date: 20030716

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040531

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1036013

Country of ref document: HK